Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses.
Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis.
Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
A new cognitive rehabilitation programme for patients with multiple sclerosis: the 'MS-line! Project'
Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases.
Treatment of HIV and Risk of Multiple Sclerosis.
Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.
Accuracy of StepWatch™ and ActiGraph Accelerometers for Measuring Steps Taken among Persons with Multiple Sclerosis.
Pregnancy in multiple sclerosis: a questionnaire study.
Mobile phones and multiple sclerosis - a nationwide cohort study in denmark.
Evaluating the potential benefit of interferon treatment in multiple sclerosis.
Ligation of the jugular veins does not result in brain inflammation or demyelination in mice.
A new prevalence study of multiple sclerosis in Orkney, Shetland and Aberdeen city.
A touch of MS: Therapeutic mislabeling.
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Polyunsaturated fatty acids in multiple sclerosis therapy.
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses.
Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.
Speedy eye movements in multiple sclerosis: Association with performance on visual and nonvisual cognitive tests.
Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study.
[Differential diagnosis of late-stage neuroborreliosis with affection of the central nervous system.]
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Remote effects of intermittent theta burst stimulation of the human pharyngeal motor system.

Pages